Welcome to our dedicated page for Movano news (Ticker: MOVE), a resource for investors and traders seeking the latest updates and insights on Movano stock.
Movano Inc. (Nasdaq: MOVE), doing business as Movano Health, generates news at the intersection of wearable medical devices, health technology, and corporate transformation. Founded in 2018, the company develops devices such as the Evie and EvieMED rings, which are designed to bring medical-grade data into consumer and enterprise wearables. Its disclosures highlight capabilities that span physiological monitoring, women’s wellness, and proprietary RF-based sensing for cuffless blood pressure and noninvasive glucose monitoring.
News coverage of Movano frequently includes product and technology updates. The company has announced clinical study results for its wrist-worn cuffless blood pressure prototype, noting accuracy within standards recognized by the FDA for wearable, cuffless blood pressure devices and the ability to collect additional vital signs such as pulse rate, SpO2, respiration rate and ECG waveforms. It has also reported enhancements to the Evie Ring’s companion app, including new personalization and trend-tracking features, integration with Apple Health, expanded workout logging, and the introduction of EvieAI, a virtual wellness assistant built from medical journal data.
Movano’s news flow also reflects regulatory and listing developments. The company has issued multiple press releases regarding Nasdaq notifications related to bid price, periodic filing timeliness, and stockholders’ equity requirements, as well as its responses, such as engaging a new independent auditor, submitting compliance plans, and implementing a one-for-ten reverse stock split to support bid price compliance. Investors following MOVE news can track how these steps affect the company’s continued listing on the Nasdaq Capital Market.
A significant portion of recent headlines centers on strategic and transactional events. Movano’s board initiated a process to explore strategic alternatives, including a sale or merger, to maximize shareholder value. This process led to a definitive Agreement and Plan of Merger with Corvex, Inc., an AI cloud computing company specializing in GPU-accelerated infrastructure. Related announcements describe the planned all-stock combination, ownership structure expectations, concurrent financings, and the intention to rename Movano Inc. as Corvex, Inc. upon closing, with the combined company headquartered in Arlington, Virginia. Movano has also communicated that it may market for sale its current operating assets, including the EvieMED Ring and its mmWave RF technology, prior to completion of the merger.
By monitoring the MOVE news feed, readers can follow updates on Movano’s wearable health products, clinical and regulatory milestones, listing status, financing activities, and the progress of its proposed merger with Corvex. This stream of information helps investors and observers understand both the company’s health technology initiatives and its potential evolution into a public vehicle for AI infrastructure through the planned combination.
Movano Health's recent survey of 1,000 U.S. women highlights the importance of data accuracy in wearable health devices. With plans for FDA clearance of its Evie Ring, Movano aims to enhance consumer trust in health data. The survey revealed that 65% of participants prioritize FDA approval for wellness metrics, emphasizing the need for reliable data to communicate with healthcare providers. While many women are interested in wearables for health management, accuracy remains a key concern. Movano seeks to position itself in the market by providing highly accurate health insights to address these needs.
Movano Inc. (NASDAQ: MOVE) will report its fourth-quarter 2022 financial results on March 20, 2023. The management will host a conference call at 9:00 a.m. PDT to discuss the results and provide a business update. The Evie Ring, aimed at women's health, is set to launch mid-2023. Movano focuses on providing medical-grade health data through consumer devices, enhancing the management of health for individuals and healthcare professionals. The company emphasizes the importance of personalized health insights, which will be integral for effective health management.
Movano Health, a healthcare solutions firm, announced on February 6, 2023, the completion of a $7.5 million public offering of 5,340,600 shares of common stock and warrants for 2,670,300 shares. The offering price was $1.40 per share, with warrants exercisable at $1.57. All securities were sold by Movano, and the net proceeds will support general corporate purposes like product development. Newbridge Securities Corporation acted as the underwriter. This offering is pivotal as Movano readies the launch of its health device, the Evie Ring, aimed at women's health, which is expected to be available in mid-2023.
Movano Health (Nasdaq: MOVE) has priced a $6.5 million underwritten public offering involving 4,644,000 shares of common stock and warrants for 2,322,000 shares. Each share and warrant is priced at $1.40 and $1.57 respectively, with the offering expected to close on January 31, 2023. The company plans to use the proceeds for general corporate purposes, including product development and commercialization. Newbridge Securities Corporation is the sole book-running manager for this offering, which may have a 30-day option for the underwriter to purchase an additional 15% of the offering.
Movano Health (Nasdaq: MOVE) announced a proposed underwritten public offering of shares and warrants to purchase common stock. The offering will be conducted by the company, which aims to grant the underwriter a 30-day option for an additional 15% of shares. Proceeds will support general corporate purposes, including product development and commercialization. Newbridge Securities Corporation is the sole book-running manager for the offering. The final terms are subject to market conditions, and the offering will be registered with the SEC. The company cautions that actual results may vary due to inherent risks and uncertainties.
Summary not available.
Summary not available.
Movano Health (Nasdaq: MOVE) plans to file for FDA clearance for its new women-focused wearable, the Evie smart ring, which integrates medical-grade health data into a user-friendly mobile app. Designed to enhance women's health insights, Evie will provide metrics including heart rate, SpO2, and menstrual tracking, aiming to empower users to make informed health decisions without a subscription fee. Following a successful hypoxia trial confirming accuracy, Evie is set to debut at CES 2023, priced below $300 and available in 2023.
Movano Health (NASDAQ: MOVE) announced promising preliminary results from its pivotal hypoxia trial, demonstrating a 2% margin of error for blood oxygen saturation (SpO2) and a heart rate error of 2 BPM. Both metrics exceeded FDA standards, indicating high accuracy. The trial involved 11 subjects and followed an FDA-required protocol. Movano plans to file for FDA clearance in 2023. CEO John Mastrototaro emphasized the importance of developing wearable devices that empower consumers with reliable health data.
Movano Health has initiated a beta program for its smart ring, designed to track and analyze medical-grade data, in collaboration with Novant Health. Approximately 30 team members from Novant will assess the smart ring's functionality and wearability. The beta program, set to commence this month, aims to prepare Movano for its product launch targeted for the first half of 2023. The collaboration underscores a shared goal of making healthcare more accessible and could provide vital feedback for Movano's technology development in consumer health.